What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.
How this was made
The 30-second read
Why it matters
The guidance raise and margin expansion are likely to boost the stock, while the mention of future M&A scrutiny tempers expectations.
Market read
BLCO's earnings beat and guidance lift provide a fresh catalyst for traders, especially those focused on healthcare and ophthalmic devices.
What to watch
Potential execution risk on upcoming FDA reviews for Project Ilios and other pipeline items.
Background
The article summarizes Bausch + Lomb's Q3 earnings call, highlighting financial performance, margin improvement, cash flow, leverage reduction, and updated full‑year guidance.
Ticker impact
Bausch + Lomb raised its 2026 revenue and EBITDA guidance and reported higher margins and cash flow in its Q3 earnings call.
likely upward pressure as investors price in stronger outlook
The company increased revenue outlook by $10 M and EBITDA guidance by $65 M, while reporting improved margins and cash generation, which are material new data.
Market effects
Eye‑care sector may see broader optimism as BLCO signals stronger demand for premium lenses and IOLs.
U.S. healthcare investors could re‑weight exposure to ophthalmic devices.
Limited to healthcare and consumer discretionary themes.
Counterpoint
If margin gains are driven by one‑off tariff refunds, the sustainable upside may be limited.
Key entities
- personAppio
Interim CEO who discussed execution and pipeline.
- personSam Eldessouky
CFO who detailed margin and cash flow metrics.
